PepGen Stock Skyrockets Over 110% on Breakthrough DM1 Trial Results
-
最新报道：PepGen Inc. (NASDAQ: PEPG) surged over 114% on September 25, 2025, after announcing unprecedented results from its FREEDOM-DM1 Phase 1 study for myotonic dystrophy type 1. The trial showed a mean splicing correction of 53.7% at the 15 mg/kg dose of PGN-EDODM1, significantly higher than any previously reported results. All patients in the highest dose cohort responded positively, with no serious adverse events. The company also priced a public offering of 31.25 million shares at $3.20 each to raise $100 million, supporting further development of its DM1 program.
下一篇
Why did Williams-Sonoma, Inc. Shares Dip in Premarket Trading Today?
- Williams-Sonoma (WSM) shares dropped 3.04% in premarket trading to $195.01 after President...
24小时热点
热点专题
416179